533 related articles for article (PubMed ID: 15339876)
1. Long-term management of patients after venous thromboembolism.
Kearon C
Circulation; 2004 Aug; 110(9 Suppl 1):I10-8. PubMed ID: 15339876
[TBL] [Abstract][Full Text] [Related]
2. Oral anticoagulant therapy in venous thromboembolism.
Cosmi B; Palareti G
Semin Vasc Med; 2003 Aug; 3(3):303-14. PubMed ID: 15199464
[TBL] [Abstract][Full Text] [Related]
3. Treatment of deep vein thrombosis.
Couturaud F; Kearon C
Semin Vasc Med; 2001; 1(1):43-54. PubMed ID: 15199513
[TBL] [Abstract][Full Text] [Related]
4. [Treatment of venous thrombosis in cancer patients: practical aspects].
Laza-Achille M; Desruennes E; Di Palma M
Bull Cancer; 2006 Mar; 93(3):271-81. PubMed ID: 16567314
[TBL] [Abstract][Full Text] [Related]
5. [The optimal duration of anticoagulant treatment following pulmonary embolism].
Couturaud F
Rev Mal Respir; 2011 Dec; 28(10):1265-77. PubMed ID: 22152935
[TBL] [Abstract][Full Text] [Related]
6. Extended treatment for venous thromboembolism: how long is long enough?
Cosmi B; Palareti G
Curr Hematol Rep; 2004 Sep; 3(5):375-81. PubMed ID: 15341706
[TBL] [Abstract][Full Text] [Related]
7. Long-term use of different doses of low-molecular-weight heparin versus vitamin K antagonists in the treatment of venous thromboembolism.
Romera-Villegas A; Cairols-Castellote MA; Vila-Coll R; Martí-Mestre X; Colomé E; Iguaz I
Ann Vasc Surg; 2010 Jul; 24(5):628-39. PubMed ID: 19932949
[TBL] [Abstract][Full Text] [Related]
8. Venous thromboembolism: risk factors for recurrence.
Zhu T; Martinez I; Emmerich J
Arterioscler Thromb Vasc Biol; 2009 Mar; 29(3):298-310. PubMed ID: 19228602
[TBL] [Abstract][Full Text] [Related]
9. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group.
Schulman S; Granqvist S; Holmström M; Carlsson A; Lindmarker P; Nicol P; Eklund SG; Nordlander S; Lärfars G; Leijd B; Linder O; Loogna E
N Engl J Med; 1997 Feb; 336(6):393-8. PubMed ID: 9010144
[TBL] [Abstract][Full Text] [Related]
10. Heparin and low-molecular-weight heparin therapy for venous thromboembolism. The twilight of anticoagulant monitoring.
Hull RD; Pineo GF; Stein P
Int Angiol; 1998 Dec; 17(4):213-24. PubMed ID: 10204652
[TBL] [Abstract][Full Text] [Related]
11. Deep venous thrombosis and pulmonary embolism. Part 2--Prevention of recurrences: warfarin or low-molecular-weight heparin for at least 3 months.
Prescrire Int; 2013 May; 22(138):129-33. PubMed ID: 23819181
[TBL] [Abstract][Full Text] [Related]
12. The outpatient bleeding risk index: validation of a tool for predicting bleeding rates in patients treated for deep venous thrombosis and pulmonary embolism.
Wells PS; Forgie MA; Simms M; Greene A; Touchie D; Lewis G; Anderson J; Rodger MA
Arch Intern Med; 2003 Apr; 163(8):917-20. PubMed ID: 12719200
[TBL] [Abstract][Full Text] [Related]
13. Heparin and low-molecular-weight heparin therapy for venous thromboembolism: will unfractionated heparin survive?
Hull RD; Pineo GF
Semin Thromb Hemost; 2004 Feb; 30 Suppl 1():11-23. PubMed ID: 15085462
[TBL] [Abstract][Full Text] [Related]
14. [Optimum duration of anticoagulant treatment after an episode of venous thromboembolism].
Couturaud F; Kearon C
Rev Pneumol Clin; 2008 Dec; 64(6):305-15. PubMed ID: 19084210
[TBL] [Abstract][Full Text] [Related]
15. What is the optimal duration of treatment for DVT? An update on evidence-based medicine of treatment for DVT.
East AT; Wakefield TW
Semin Vasc Surg; 2010 Sep; 23(3):182-91. PubMed ID: 20826296
[TBL] [Abstract][Full Text] [Related]
16. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism.
Ridker PM; Goldhaber SZ; Danielson E; Rosenberg Y; Eby CS; Deitcher SR; Cushman M; Moll S; Kessler CM; Elliott CG; Paulson R; Wong T; Bauer KA; Schwartz BA; Miletich JP; Bounameaux H; Glynn RJ;
N Engl J Med; 2003 Apr; 348(15):1425-34. PubMed ID: 12601075
[TBL] [Abstract][Full Text] [Related]
17. Emerging anticoagulants for the treatment of venous thromboembolism.
Weitz JI
Thromb Haemost; 2006 Sep; 96(3):274-84. PubMed ID: 16953267
[TBL] [Abstract][Full Text] [Related]
18. Prognostic factors for recurrence of venous thromboembolism (VTE) or bleeding during long-term secondary prevention of VTE with ximelagatran.
Eriksson H; Lundström T; Wåhlander K; Clason SB; Schulman S;
Thromb Haemost; 2005 Sep; 94(3):522-7. PubMed ID: 16268466
[TBL] [Abstract][Full Text] [Related]
19. Duration of anticoagulant therapy after initial idiopathic venous thromboembolism.
Frazee LA; Chomo DL
Ann Pharmacother; 2003 Oct; 37(10):1489-96. PubMed ID: 14519045
[TBL] [Abstract][Full Text] [Related]
20. [Duration of antivitamin K therapy in venous thromboembolic disease].
Ferrari E; Baudouy M; Morand P
Arch Mal Coeur Vaiss; 1995 Dec; 88(12):1891-4. PubMed ID: 8729371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
